Bladder Cancer Clinical Trial
Official title:
A Phase IV Investigation of Sugammadex in Outpatient Urological Procedures
The goal of this clinical research study is to determine whether using sugammadex, given with
a standard muscle relaxation drug during bladder surgeries, improves anesthesia conditions
and recovery time.
During some bladder operations, your muscles must be completely relaxed. Muscle relaxation
drugs cause the muscles to relax, including the respiratory muscles, and as a result
artificial ventilation is needed to help you breathe. Sugammadex and other standard drugs
reverse the effect of the muscle relaxation drugs, allowing you to breathe on your own after
the operation.
Study Groups:
If you agree to take part in this study, you will be randomly assigned (as in the flip of a
coin) to 1 of 2 study groups. This is done because no one knows if one study group is better,
the same, or worse than the other group:
- If you are in Group 1, you will receive sugammadex to reverse the muscle relaxation.
- If you are in Group 2, you will receive the standard of care
(neostigmine/glycopyrrolate) to reverse the muscle relaxation.
You and the surgeon will not know which group you have been assigned to. However, the
anesthesiologist and study staff will know.
Length of Study:
You will be on study for up to 1 week after the cystoscopy. If you are unable to have the
procedure performed, you may be taken off study early.
This is an investigational study. Sugammadex and neostigmine/glycopyrrolate are all FDA
approved and commercially available to reverse muscle relaxation. The comparison of these
drugs is investigational.
Up to 50 participants will take part in this study. All will be enrolled at MD Anderson.
Study Procedures:
Before the cystoscopy, we will collect your basic information and medical history. We will
take your vital signs and the anesthesiologist will perform routine assessments. This will
take about 30-60 minutes to complete.
Before the cystoscopy, you will be given rocuronium to relax your muscles. After the
procedure, you will receive either sugammadex or the standard of care to reverse the
relaxation.
After you are extubated (the tube is removed from your throat), we will assess how fast the
relaxation drugs the anesthesiologist gave you wear off (stop working), using a small
monitoring device that will be attached to your wrist. This is the only research test that
will be done right after surgery.
If you are still in the hospital 1 day after the cystoscopy, a member of the staff will ask
you the series of questions. If you have been sent home, you will be called and you will
complete them by phone.
Researchers will also collect information about your cystoscopy procedure and recovery from
your medical record. This collection will continue for up to 1 week after surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |